Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

Bone Marrow Transplantation volume 36, pages 553–554 (2005)Cite this article

We read with great interest the prognostic model recently developed by Hahn et al1 for predicting event-free survival (EFS) after stem cell transplantation (SCT) for relapsed and/or refractory Hodgkin's disease (HD). However, we would like to comment further on the suggestion of potentially using such a model for selecting different and/or ‘novel’ allogeneic transplant approaches in this group of patients.

Over the last 14 years, we have performed a total of 12 allogeneic transplants for relapsed and/or refractory HD. Myeloablative conditioning was used in six cases (cyclophosphamide/TBI and busulphan/cyclophosphamide in three cases each), and nonmyeloablative preparative regimens in six (fludarabine/TBI in four, fludarabine/cyclophosphamide in one and fludarabine/melphalan in one). Donors included fully HLA-matched siblings in seven cases, single-HLA mismatched siblings in three and HLA-matched volunteer unrelated donors in two. Stem cell source used included G-CSF stimulated peripheral blood progenitor cells in eight cases and bone marrow in four. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine/methotrexate (days 1, 3, 6 ±11), or in the fludarabine/TBI conditioned patients, cyclosporine and mycophenolate mofetil.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Hahn T, Benekli M, Wong C et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005; 35: 557–566.

    Article  CAS  Google Scholar 

  2. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291–1296.

    Article  CAS  Google Scholar 

  3. Freytes CO, Loberiza FP, Rizzo JD et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797–3803.

    Article  CAS  Google Scholar 

  4. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316.

    Article  CAS  Google Scholar 

  5. Sureda A, Schmitz N . Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin's disease. Ann Oncol 2002; 13 (Suppl 1): 128–132.

    Article  Google Scholar 

  6. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918–3924.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Royal Brisbane Hospital, Brisbane, Qld, Australia

    S Tey, J Butler, S Durrant, G Hill, J Morton & G Kennedy

Authors
  1. S Tey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Durrant
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tey, S., Butler, J., Durrant, S. et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 36, 553–554 (2005). https://doi.org/10.1038/sj.bmt.1705044

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705044

This article is cited by

Search

Advanced search

Quick links